Impact of Cellular Immune Function on Prognosis of Lung Cancer Patients after Cytokine-induced Killer Cell Therapy

Abstract

Aims: To investigate changes in cellular immune function of patients with lung cancer before and after cytokineinduced killer (CIK) cell therapy and to identify variation effects on overall survival (OS) and progression-free survival (PFS). Materials and Methods:A total of 943 lung cancer patients with immune dysfunction were recruited from January 2002 to January 2010, 532 being allocated to conventional therapy and 411 to CIK therapy after a standard treatment according to the NCCN Clinical Practice Guidelines. All the patients were investigated for cellular immune function before and after therapy every three months. and clinical prognostic outcomes were analyzed. Results: After six courses of treatment, immune function was much improved in patients receiving CIK cells therapy as compared to controls. The percentages of recurrence and/or metastases for patients undergoing CIK cell therapy was 56.2% and 49.1% respectively but 78.6% and 70.3% among controls (p<0.001). The median OS times for CIK cell therapy and control groups were 48 and 36 months respectively. The OS rates at 12, 36, 60, 84 months in CIK treated patients were 97.8%, 66.9%, 27.7%, and 4.1% while they were 92.3%, 44.5%, 9.2%, and 1.5% in controls. OS and PFS were significantly different by log rank test between the two groups and across the three immune improvement classes. Conclusions: The immune function of lung cancer patients was improved by CIK cell therapy, associated with an increase in the OS rate and extension of the time to recurrence and/or metastasis.

Effect of Chinese Medicine XIAOJI Decoction Combined with Platinum-Based Chemotherapy and Transfusion of Cytokine-Induced Killer Cells in Patients with Stage III B/IV Non-Small Cell Lung Cancer

“…On the other hand, CIK cell infusion can improve the immune function of patients, which was consistent with other studies [27][28][29][30], indicating that maintaining and enhancing immune functions played a crucial role in improving quality of life and survival in lung cancer patients. There was only 1 case of mild fever in treatment group after treatment, while the patient could relieve by symptomatic treatment.…”

Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer

“…These findings might indicate that the malnutritional status may impair the efficacy of adjuvant chemotherapy. Previous data have shown that improved immune function reduced the recurrence rate and prolonged the survival of patients postoperatively [ 36 , 37 ]. We consider that the high PNI group benefited from the combined anti-cancer impact of chemotherapy and enhanced immune function, and thus, no difference in survival was found between patients who received less than 6 and 6–8 cycles of adjuvant chemotherapy.…”

Continuous DC-CIK Infusions Restore CD8+Cellular Immunity, Physical Activity and Improve Clinical Efficacy in Advanced Cancer Patients Unresponsive to Conventional Treatments

“…Cancer immunotherapy has become a frontier approach in the last 5 years, convincing evidences come out of several clinical trials. The clinical benefits were seen from the previous studies, regarding to lung cancer (Han et al, 2014;Jin et al, 2014;Shi et al, 2014), breast cancer (Ren et al, 2013), renal cancer (Wang et al, 2014a and gastrointestinal cancer (Shi et al, 2012;Gao et al, 2014;Wang et al, 2014b) etc. DCs have been proven as the most effective antigen-presenting cells, which can digest by endocytose antigens including circulating tumorassociated antigens to elicit the general immune responses and diminish T cell exhausting (Liu et al, 2009;Zhao et al, 2014).…”